These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38519988)

  • 1. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
    Streichart L; Felldin M; Ekberg J; Mjörnstedt L; Lindnér P; Lennerling A; Bröcker V; Mölne J; Holgersson J; Daenen K; Wennberg L; Lorant T; Baid-Agrawal S
    Trials; 2024 Mar; 25(1):213. PubMed ID: 38519988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.
    Khairallah P; Robbins-Juarez S; Patel S; Shah V; Toma K; Fernandez H; Dube GK; King K; Mohan S; Husain SA; Morris H; Crew RJ
    Clin Transplant; 2023 Jan; 37(1):e14853. PubMed ID: 36398915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
    Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
    Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
    Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
    Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
    Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA
    Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
    Doberer K; Duerr M; Halloran PF; Eskandary F; Budde K; Regele H; Reeve J; Borski A; Kozakowski N; Reindl-Schwaighofer R; Waiser J; Lachmann N; Schranz S; Firbas C; Mühlbacher J; Gelbenegger G; Perkmann T; Wahrmann M; Kainz A; Ristl R; Halleck F; Bond G; Chong E; Jilma B; Böhmig GA
    J Am Soc Nephrol; 2021 Mar; 32(3):708-722. PubMed ID: 33443079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients.
    Sangermano M; Negrisolo S; Antoniello B; Vadori M; Cozzi E; Benetti E
    Hum Immunol; 2024 Sep; 85(5):111088. PubMed ID: 39146803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.
    Arrivé C; Bazzoli C; Jouve T; Noble J; Rostaing L; Stanke-Labesque F; Djerada Z
    BioDrugs; 2024 Sep; 38(5):703-716. PubMed ID: 39147956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMP Is Discriminative for Chronic Active Antibody-Mediated Rejection and Associate With Intimal Arteritis in Kidney Transplantation.
    Zhan P; Li H; Han M; Wang Z; Zhao J; Tu J; Shi X; Fu Y
    Front Immunol; 2021; 12():661911. PubMed ID: 33897709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
    Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
    Front Immunol; 2022; 13():839380. PubMed ID: 35493469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation.
    Morozumi K; Takeda A; Otsuka Y; Horike K; Gotoh N; Narumi S; Watarai Y; Kobayashi T
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():4-8. PubMed ID: 26971899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients.
    Ho J; Sharma A; Kroeker K; Carroll R; De Serres S; Gibson IW; Hirt-Minkowski P; Jevnikar A; Kim SJ; Knoll G; Rush DN; Wiebe C; Nickerson P
    BMJ Open; 2019 Apr; 9(4):e024908. PubMed ID: 30975673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.
    Berger M; Baliker M; Van Gelder T; Böhmig GA; Mannon RB; Kumar D; Chadban S; Nickerson P; Lee LA; Djamali A
    Transplantation; 2024 May; 108(5):1109-1114. PubMed ID: 37941113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
    Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Belatacept Conversion on Renal Function, Histology, and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection.
    Kumar D; Raynaud M; Chang J; Reeve J; Yakubu I; Kamal L; Levy M; Bhati C; Kimball P; King A; Massey D; Halloran P; Gupta G
    Transplantation; 2021 Mar; 105(3):660-667. PubMed ID: 32510913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.